Pacific Marine Biotech

What Pacific Marine Biotech does

Pacific Marine Biotech (PMB) is a privately held, clinical-stage biotechnology company founded in December 2021 by Samuel Grant and Alan Temkin. Headquartered in Torrington, Connecticut with an Australian subsidiary in Brisbane, Queensland, PMB is developing Immune12 — a proprietary orally administered marine-derived complex biologic — for the treatment of Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG), both orphan-designated brain cancers with no curative treatment options. Immune12 is manufactured by Unicorn Pacific at their Vanuatu facility using a patented proprietary formula combining warm-water sea cucumber (Black Teatfish and Sandfish), sea urchin, sea squirt, and sargassum, with each 20ml sachet flash frozen and shipped for clinical trial distribution.

The product has demonstrated broad-spectrum cytotoxic activity across 18 tumor cell lines (including 6 GBM lines) with IC50 values ranging from 0.1% to 1.4% v/v, favorable safety in 28-day mouse toxicity studies, and selective tumor cell killing with lower toxicity to healthy brain tissue in preclinical evaluation at UNC Eshelman Innovation. PMB is currently running a Phase 2 clinical trial in Australia (ANZCTR12624001484538) actively recruiting 60 GBM patients and has an FDA application in progress for US-based Phase 2 trials.

The company's revenue model is pre-commercial and based on future pharmaceutical product sales upon regulatory approval, with potential licensing as an alternative commercialization pathway. PMB engages in a clinical-trials-based go-to-market motion, partnering with healthcare institutions, clinical researchers, FDA/TGA regulatory bodies, and patient advocacy organizations (EndBrainCancer.org) to advance Immune12 through regulatory approval. The current GTM focuses on building KOL relationships through conferences (COGNO, LSX, SNO) and driving trial enrollment through community-led patient advocacy partnerships in the neuro-oncology space.

Name

Pacific Marine Biotech

Legal name

Pacific Marine Biotech, LLC

Website

https://pacificmarinebiotech.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Pacific Marine Biotech is a clinical-stage biotech developing Immune12, a marine-derived oral complex biologic targeting Glioblastoma Multiforme (GBM) and DIPG. Founded in 2021 and headquartered in Torrington, CT, the company is currently running Phase 2 trials in Australia with US FDA applications in progress.

Ownership category

akta.pro rank

Product category

Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• Marine biotechnology
• Oncology therapeutics
• Glioblastoma treatment
• Complex biologics
• Clinical drug development

Headquarters

HQ city

Torrington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Future pharmaceutical product revenue: PMB is a pre-revenue biotech company in the clinical development stage. Its revenue model will be based on the eventual commercialization of Immune12 as an FDA-approved pharmaceutical product for the treatment of GBM and other cancers. Currently, the company is focused on securing regulatory approvals (FDA, TGA) through Phase 2 clinical trials. No revenue is currently generated as Immune12 is an investigational product not available to the general public.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Pacific Marine Biotech develops Immune12, a proprietary marine-sourced complex biologic combining warm-water sea cucumber (Black Teatfish and Sandfish), sea urchin, sea squirt, and sargassum, manufactured by Unicorn Pacific in Vanuatu. The product is being evaluated in a Phase 2 clinical trial (ANZCTR12624001484538) recruiting 60 GBM patients at multiple Australian sites, with parallel US FDA preparations underway. Immune12 is delivered as a 20ml oral sachet designed for at-home administration and is differentiated from standard-of-care by selective tumor cytotoxicity, a favorable preclinical safety profile, and oral bioavailability.

Product overview

Pacific Marine Biotech operates as a single-product biotech company developing Immune12, an investigational marine-sourced complex biologic. The product is derived from a proprietary formulation combining two types of warm water sea cucumber (Black Teatfish and Sandfish), sea urchin, sea squirt, and sargassum (brown sea grass). Immune12 is manufactured by Unicorn Pacific at their facility in Vanuatu and is being evaluated in Phase 2 clinical trials for glioblastoma and DIPG. The company focuses exclusively on advancing this one therapeutic candidate through FDA and international regulatory approvals.

Differentiator

Problem solved

Functional benefit

Brands

• Immune12: Proprietary investigational product - a complex biologic derived from marine-sourced ingredients being evaluated for cancer treatment, specifically targeting Glioblastoma (GBM) and DIPG

Products and services

• Immune12 Investigational proprietary marine-sourced complex biologic combining warm-water sea cucumber (Black Teatfish and Sandfish), sea urchin, sea squirt, and sargassum, manufactured by Unicorn Pacific in Vanuatu. Delivered as an oral 20ml sachet for at-home administration, undergoing clinical evaluation for the treatment of Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG).

Quantifiable outcome

• IC50 values ranging from 0.1% to 1.4% v/v in media across 18 tumor cell lines including 6 GBM lines
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• EndBrainCancer.org (EBCI)coreGTM or Marketing Partner · 12 May 2026Pacific Marine Biotech serves as a Patient Engagement Partner with EndBrainCancer.org (EBCI). EBCI provides increased access to specialists and treatment options for patients through collaborative efforts with various partners around the globe. Corporate partners demonstrate their commitment to the mission of EBCI through educational/outreach meeting and event sponsorships. This partnership supports PMB's patient recruitment and awareness-building efforts for its GBM clinical trials.
• University of North Carolina (UNC) / Eshelman InnovationcoreStrategic or Co-development PartnerAndrew Satterlee, PhD, Assistant Professor and Founding Director of the Screening Live Cancer Explants Program at UNC Eshelman Innovation, leads preclinical evaluations of Immune12. UNC conducts comprehensive investigation including proteomic, peptidomic, and metabolomic profiling, in vitro cytotoxicity assays across tumor cell lines, and in vivo toxicity and efficacy studies in mouse models.
• Southern Cross UniversitycoreStrategic or Co-development PartnerDr. Janet Schloss from Southern Cross University serves as the principal investigator for PMB's Phase 2 clinical trial of Immune12 for GBM in Australia. She presented abstract A46JZAJ549 on the IMMUNE-12 trial at the COGNO 2025 Annual Scientific Meeting.
• Unicorn PacificcoreOEM/ Whitelabel/ Licensing PartnerImmune12 is manufactured by Unicorn Pacific (founded 1982) at their facility in Vanuatu in the South Pacific using a patented proprietary formula. Unicorn Pacific is a leader in marine biotechnology. PMB's relationship with Unicorn Pacific stems from the original TBL-12 formula developed by Sam Grant Sr. and manufactured by the company for decades. Each 20ml sachet is processed, flash frozen, boxed, and shipped to New Zealand for trial and laboratory distribution.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Denovo Biopharma: Clinical-stage oncology biotech developing biomarker-driven therapies including for glioblastoma. Comparable as a small-cap clinical-stage company pursuing novel mechanisms in GBM.
• Mustang Bio: Clinical-stage cell and gene therapy biotech with active GBM programs. Comparable as a small-cap clinical-stage company developing novel therapeutics for malignant gliomas.
• Novocure: Commercial-stage oncology company commercializing Optune, a device therapy approved for newly diagnosed and recurrent GBM. Directly comparable as a focused GBM therapeutics company with approved product addressing the same indication.
• Diffusion Pharmaceuticals: Clinical-stage biotech developing small molecule therapies for GBM and other cancers. Comparable as a small-cap clinical-stage oncology company with active GBM development programs.
• Moleculin Biotech: Clinical-stage oncology biotech developing small molecule therapies for brain tumors and other cancers. Comparable as a small-cap oncology biotech pursuing regulatory pathways in oncology indications.
• CNS Pharmaceuticals: Clinical-stage oncology biotech developing treatments for primary and metastatic brain cancers including GBM. Directly comparable as a small-cap, single-indication-focused GBM therapeutic developer in similar clinical stage.
• PharmaMar: Spanish biopharmaceutical company specializing in marine-derived oncology drugs including Yondelis and Aplidin. Directly comparable for the marine-sourced biologic origin and oncology focus, with established track record validating marine compound therapeutics.

Emerging players

• VBI Vaccines: Clinical-stage biotech developing vaccines including immunotherapeutic approaches for GBM. Partial overlap as a clinical-stage developer of novel immunotherapies for brain tumors.

Broad incumbents

• Bristol-Myers Squibb: Global pharmaceutical company with CheckMate trials evaluating Opdivo (nivolumab) in GBM. Comparable as a large incumbent with active GBM clinical programs and broad neuro-oncology footprint that could serve as potential partner or acquirer.
• Eisai Co. Major Japanese pharmaceutical company with approved marine-derived oncology drug Halaven (eribulin) and a lenvatinib GBM program. Comparable as a large oncology player with marine-derived therapeutic expertise and active GBM development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@PacificMarineBiotech
• LinkedInlinkedin.com/company/pacific-marine-biotech-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pacific Marine Biotech